JP2019526262A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526262A5
JP2019526262A5 JP2019512264A JP2019512264A JP2019526262A5 JP 2019526262 A5 JP2019526262 A5 JP 2019526262A5 JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019526262 A5 JP2019526262 A5 JP 2019526262A5
Authority
JP
Japan
Prior art keywords
gene
recombinant
lab
pharmaceutical composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512264A
Other languages
English (en)
Japanese (ja)
Other versions
JP7016865B2 (ja
JP2019526262A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055287 external-priority patent/WO2018042390A1/en
Publication of JP2019526262A publication Critical patent/JP2019526262A/ja
Publication of JP2019526262A5 publication Critical patent/JP2019526262A5/ja
Priority to JP2022010063A priority Critical patent/JP2022061035A/ja
Application granted granted Critical
Publication of JP7016865B2 publication Critical patent/JP7016865B2/ja
Priority to JP2024009123A priority patent/JP2024047590A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512264A 2016-09-02 2017-09-02 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌 Expired - Fee Related JP7016865B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022010063A JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383079P 2016-09-02 2016-09-02
US62/383,079 2016-09-02
PCT/IB2017/055287 WO2018042390A1 (en) 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing il-10 and insulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010063A Division JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Publications (3)

Publication Number Publication Date
JP2019526262A JP2019526262A (ja) 2019-09-19
JP2019526262A5 true JP2019526262A5 (cg-RX-API-DMAC7.html) 2020-10-15
JP7016865B2 JP7016865B2 (ja) 2022-03-03

Family

ID=60120085

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512264A Expired - Fee Related JP7016865B2 (ja) 2016-09-02 2017-09-02 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2022010063A Pending JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A Pending JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022010063A Pending JP2022061035A (ja) 2016-09-02 2022-01-26 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌
JP2024009123A Pending JP2024047590A (ja) 2016-09-02 2024-01-25 Il-10およびインスリンを安定的に発現する遺伝子改変された細菌

Country Status (8)

Country Link
US (3) US10858663B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506932B1 (cg-RX-API-DMAC7.html)
JP (3) JP7016865B2 (cg-RX-API-DMAC7.html)
CN (2) CN118813511A (cg-RX-API-DMAC7.html)
AU (1) AU2017319707B2 (cg-RX-API-DMAC7.html)
CA (1) CA3035151A1 (cg-RX-API-DMAC7.html)
RU (1) RU2768027C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018042390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858663B2 (en) * 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
KR102469701B1 (ko) 2016-09-13 2022-11-22 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
EP0628083A1 (en) 1992-02-27 1994-12-14 Microbial Technics Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
US6348187B1 (en) 1996-01-24 2002-02-19 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
ES2197364T3 (es) 1996-09-18 2004-01-01 Erling Johansen Baño bucal comprendiendo iones de calcio y fosfato en solucion sobresaturada.
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
WO2000018377A1 (en) 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
CA2446776C (en) 2001-05-03 2011-07-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
AU2003247881A1 (en) 2002-07-08 2004-01-23 Joe S. Wilkins Jr. Antibacterial formulations
WO2004056850A2 (en) * 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
CN101605900B (zh) * 2007-01-12 2014-04-23 阿克图杰尼斯公司 乳球菌启动子和其用途
BRPI0807857A2 (pt) * 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Jnc株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
ES2425385T3 (es) 2009-04-30 2013-10-15 Actogenix N.V. Crioprotectores para la liofilización de las bacterias de ácido láctico
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
CN103917639B (zh) * 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
HUE038830T2 (hu) * 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
US10858663B2 (en) * 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin

Similar Documents

Publication Publication Date Title
AU2017208153B2 (en) Compositions and methods for the treatment of type 1 diabetes
Heiseke et al. CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell–mediated protection from colitis
Rutella et al. Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease
CN113286615A (zh) 用于治疗癌症的微生物和免疫调节剂的组合疗法
US20230348918A1 (en) Genetically Modified Bacteria Stably Expressing IL-10 and Insulin
Huss et al. TGF‐β signaling via Smad4 drives IL‐10 production in effector Th1 cells and reduces T‐cell trafficking in EAE
KR101291960B1 (ko) 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달
CN113056479A (zh) 腺病毒疫苗媒介物中的cd40和cd40l结合物
US20080026986A1 (en) Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
TW201833323A (zh) 重組李斯特菌屬疫苗菌株及在癌症免疫治療中使用該菌株之方法
WO2013158553A1 (en) Multivalent breast cancer vaccine
KR20220092523A (ko) 변이체 인터루킨-2 (vIL-2) 폴리펩타이드를 코딩하는 종양용해성 바이러스 벡터
Torres et al. IL-12p40/IL-10 producing preCD8α/Clec9A+ dendritic cells are induced in neonates upon Listeria monocytogenes infection
Salio Unconventional MAIT cell responses to bacterial infections
Cannon et al. Cellular immunotherapy for ovarian cancer
Roider et al. Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer
WO2022086988A1 (en) Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides
KR20220113674A (ko) 셀리악 병의 치료
Kong et al. Expression of fusion IL2-B7. 1 (IgV+ C) and effects on T lymphocytes
CN120476198A (zh) 分泌白介素-10的细菌
Memory Differential Requirements for OX40 Signals